Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydantoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | MB | P02144 | 2/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL10636755 | 0.93 | CRBN (0.42) | CRBNMBPDE3BPDE3A | |
| Hydantoin SCHEMBL28140889 | 0.90 | CRBN (0.44) | CRBNMBITGB3ITGB1ITGAV | |
| Hydantoin SCHEMBL11127367 | 0.86 | CRBN (0.41) | CRBNMBPDE3BPDE3A | |
| Hydantoin SCHEMBL27705088 | 0.84 | CRBN (0.52) | CRBNMBPDE3BPDE3A | |
| Hydantoin SCHEMBL27690 | 0.84 | — | — | |
| Hydantoin SCHEMBL7285865 | 0.84 | — | — | |
| Hydantoin SCHEMBL28531040 | 0.84 | CRBN (0.33) | CRBN | |
| Hydantoin SCHEMBL27655704 | 0.84 | CRBN (0.39) | CRBNMBITGB3ITGB1ITGAV | |
| Hydantoin SCHEMBL16971290 | 0.83 | CRBN (0.42) | CRBNMB | |
| Hydantoin SCHEMBL27574136 | 0.82 | CRBN (0.46) | CRBNMBPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5939556-A | Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-17 | — | — | US | claimed |
| EP-0628571-A1 | NOVEL PEPTIDE, AND ANTITHROMBOTIC AGENT, ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION, CELL FUSION INHIBITOR, CANCER METASTASIS INHIBITOR, PROTECTIVE FOR PLATELET PREPARATION FOR TRANSFUSION AND PACK OF PLATELET PREPARATION FOR TRANSFUSION | NIPPON STEEL CORPORATION (JP) | 1994-12-14 | — | — | EP | claimed |
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | claimed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-101379138-B | Conductive polymer solution, conductive coating film, capacitor and method for producing same | 信越聚合物株式会社 | 2019-03-22 | — | — | CN | disclosed |
| CN-109153644-A | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H·李·莫菲特癌症中心研究有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-104496912-A | Preparation method for orotic acid | INST SUBTROPICAL AGRI CAS | 2015-04-08 | — | — | CN | disclosed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| CN-100398521-C | 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | CN | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| CN-1125054-C | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICS GMBH (DE) | 2003-10-22 | — | — | CN | disclosed |
| CN-1267210-A | Hair styling composition | PROCTER & GAMBLE (US) | 2000-09-20 | — | — | CN | disclosed |
| US-5939556-A | Hydantoin compounds, salts thereof, processes for their preparation, and processes for preparing pharmaceutically active compounds comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-08-17 | — | — | US | disclosed |
| CN-1218047-A | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-06-02 | — | — | CN | disclosed |
| CN-1037975-C | Curable suspensions of epoxy resins | CIBA GEIGY AG (CH) | 1998-04-08 | — | — | CN | disclosed |
| US-5498601-A | RGD SEQUENCE | NIPPON STEEL CORPORATION (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0628571-A1 | NOVEL PEPTIDE, AND ANTITHROMBOTIC AGENT, ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION, CELL FUSION INHIBITOR, CANCER METASTASIS INHIBITOR, PROTECTIVE FOR PLATELET PREPARATION FOR TRANSFUSION AND PACK OF PLATELET PREPARATION FOR TRANSFUSION | NIPPON STEEL CORPORATION (JP) | 1994-12-14 | — | — | EP | disclosed |
| CN-1083082-A | Curable suspensions of epoxy resins | CIBA GEIGY AG (CH) | 1994-03-02 | — | — | CN | disclosed |
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | disclosed |